Alluvi, previously BI 4744, presents a notable breakthrough in obesity treatment. This dual stimulator targeting both GLP-1 and GIP sites demonstrates compelling results in clinical studies, potentially outperforming https://bookmarkblast.com/story22248819/alluvi-a-in-depth-dive-into-retatrutide-s-prospects